Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wioleta M Zelek

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Bio-Protocol|November 1, 2021
Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement PathwayWioleta M Zelek
Clinical Chemistry|July 16, 2024
Is Long COVID a Complement Dysregulation Disease?Wioleta M Zelek
Immunobiology|May 15, 2023
Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to knowWioleta M Zelek, Richard A Harrison
Trends in Pharmacological Sciences|March 11, 2022
Targeting complement in neurodegeneration: challenges, risks, and strategiesWioleta M Zelek, B Paul Morgan
Frontiers in Immunology|January 11, 2021
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple SpeciesWioleta M Zelek, B Paul Morgan
Immunobiology|June 22, 2025
Complement therapeutics in neurodegenerative diseasesWioleta M Zelek, Andrea J Tenner
European Journal of Immunology|June 19, 2026
Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and HurdlesMarco Mannes, Wioleta M Zelek, Leendert A Trouw
Brain, Behavior, and Immunity|March 14, 2024
Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementiaWioleta M Zelek, Ryan J Bevan, Bryan Paul Morgan
Immunology|May 24, 2019
Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple speciesWioleta M Zelek, Philip R Taylor, B Paul Morgan
Immunobiology|July 24, 2018
Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffersWioleta M Zelek, Claire L Harris, B Paul Morgan
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Bio-Protocol|November 1, 2021
Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement PathwayWioleta M Zelek
Clinical Chemistry|July 16, 2024
Is Long COVID a Complement Dysregulation Disease?Wioleta M Zelek
Immunobiology|May 15, 2023
Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to knowWioleta M Zelek, Richard A Harrison
Trends in Pharmacological Sciences|March 11, 2022
Targeting complement in neurodegeneration: challenges, risks, and strategiesWioleta M Zelek, B Paul Morgan
Frontiers in Immunology|January 11, 2021
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple SpeciesWioleta M Zelek, B Paul Morgan
Immunobiology|June 22, 2025
Complement therapeutics in neurodegenerative diseasesWioleta M Zelek, Andrea J Tenner
European Journal of Immunology|June 19, 2026
Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and HurdlesMarco Mannes, Wioleta M Zelek, Leendert A Trouw
Brain, Behavior, and Immunity|March 14, 2024
Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementiaWioleta M Zelek, Ryan J Bevan, Bryan Paul Morgan
Immunology|May 24, 2019
Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple speciesWioleta M Zelek, Philip R Taylor, B Paul Morgan
Immunobiology|July 24, 2018
Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffersWioleta M Zelek, Claire L Harris, B Paul Morgan
Pageof 5